11 terminated. 11 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Terminated 11 |
| Phase 2 | 3 | Terminated 3 |
Follow Nephritis: new trials by email Literature Review of Nephritis trials Research Report on Nephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus YTS109 cell injection - Lupus Nephritis (LN), Immune Thrombocytopenia (ITP) | Phase 1 | Terminated | China Immunotech (Beijing) Biotechnology Co., Ltd. | 2 | 2025-04-16 | 2026-10-14 |
| KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen - Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III | Phase 1 / Phase 2 | Terminated | Kyverna Therapeutics | 6 | 2023-04-28 | 2026-08-31 |
| KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen - Lupus Nephritis, Lupus Nephritis - WHO Class III | Phase 1 / Phase 2 | Terminated | Kyverna Therapeutics | 2 | 2022-12-01 | 2026-08-31 |
| Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy VB119 - Membranous Nephropathy | Phase 1 / Phase 2 | Terminated | Tenet Medicines | 6 | 2021-05-05 | 2026-02-12 |
| Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN) Ixazomib, Placebo - Lupus Nephritis | Phase 1 | Terminated | Takeda | 12 | 2014-06-09 | 2019-04-08 |
| Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease CDX-1135 - Dense Deposit Disease, Membranoproliferative Glomerulonephritis Type II | Phase 1 | Terminated | Celldex Therapeutics | 1 | 2013-01-01 | 2014-03-07 |
| Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil Atacicept - Lupus Nephritis | Phase 1 | Terminated | EMD Serono | 1 | 2011-06-01 | 2013-10-22 |
| Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy OPL-CCL2-LPM - IGA Nephropathy, Proteinuria | Phase 1 | Terminated | Osprey Pharmaceuticals USA, Inc. | 30 | 2009-03-01 | 2010-06-02 |
| Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor Galactose - Focal Segmental Glomerulosclerosis | Phase 1 | Terminated | Northwell Health | 15 | 2008-12-01 | 2015-09-10 |
| Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS) FG-3019 - Focal Segmental Glomerulosclerosis | Phase 1 | Terminated | Kyntra Bio | 2 | 2008-04-01 | 2019-07-31 |
| Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus TRU-015 - Systemic Lupus Erythematosus | Phase 1 | Terminated | Wyeth is now a wholly owned subsidiary of Pfizer | 20 | 2007-08-01 | 2008-05-08 |
Lupus Nephritis (5) · Autoimmune Diseases (2) · Glomerulonephritis (2) · Glomerulonephritis, Membranous (2) · Glomerulosclerosis, Focal Segmental (2) · Lupus Erythematosus, Systemic (2) · Glomerulonephritis, IGA (1) · Glomerulonephritis, Membranoproliferative (1) · Proteinuria (1) · Purpura, Thrombocytopenic, Idiopathic (1)
Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Kidney Diseases (11) · Male Urogenital Diseases (11) · Urogenital Diseases (11) · Urologic Diseases (11) · Glomerulonephritis (9) · Immune System Diseases (9) · Autoimmune Diseases (6) · Connective Tissue Diseases (6) · Skin and Connective Tissue Diseases (6) · Lupus Erythematosus, Systemic (4) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2)
Cyclophosphamide (2) · fludarabine (2) · Galactose (1) · TACI receptor-IgG Fc fragment fusion protein (1) · TRU-015 protein (1) · ixazomib (1) · pamrevlumab (1)
Kyverna Therapeutics (2) · Celldex Therapeutics (1) · China Immunotech (Beijing) Biotechnology Co., Ltd. (1) · EMD Serono (1) · Kyntra Bio (1) · Northwell Health (1) · Osprey Pharmaceuticals USA, Inc. (1) · Takeda (1) · Tenet Medicines (1) · Wyeth is now a wholly owned subsidiary of Pfizer (1)
United States (7) · Germany (2) · Canada (1) · China (1) · France (1) · Italy (1) · Russia (1) · Spain (1) · United Kingdom (1)
Bryan Curtis, M.D. (1) · Carla Nester, MD, MSA (1) · Howard Trachtman, MD (1) · Michelle Hladunewich, M.D. (1) · Richard Smith, MD (1) · Vincent Pichette, M.D., Ph.D. (1)
2014 (1)